Findings presented at AAD26 highlight rapid onset and deepening responses through week 24

A late-March formulary update may change how often tirbanibulin is a realistic option in clinic.

Increasing birth length positively associated with atopic dermatitis by age 3 years, while inverse association seen for short birth length

Guidelines also developed for medical management of pediatric atopic dermatitis, including 27 evidence-based recommendations

Increased mortality seen with primary tumor location in head and neck site; mortality reduced for location in upper limb/shoulder and lower limb/hip

Definitions developed for low disease activity, very low disease activity, remission in atopic dermatitis

An oral TYK2 inhibitor now carries an indication across both skin and joint disease

Atopic dermatitis rarely behaves the same way twice, which means the real work of treating it begins in everything we don’t immediately see.

Sometimes the smallest structure in the exam, the nail, offers some of the clearest clues to what’s really going on beneath the surface.

Major criteria for vitiligo include spread or active disease, involvement of highly visible or high-impact areas, psychological distress

Phase 3 studies show the highly selective oral tyrosine kinase 2 inhibitor provides rapid, durable skin improvement

Benefits include total and facial repigmentation in patients 12 years and older versus placebo

Ixekizumab plus tirzepatide tied to simultaneous benefit of American College of Rheumatology 50 percent improvement and weight reduction

Findings seen for skin clearance and disease severity with both every-four-week and every-12-week dosing

Topical melatonin improves hydration and firmness and reduces wrinkle depth and surface roughness in clinical studies

Sensitivity of DERM+ for identifying melanoma was 93.7 percent and for SCC, BCC was 100 and 99.2 percent

Authors say universal screening of all children with atopic dermatitis is unlikely to improve identification of early cardiovascular risk

Higher superficial SSI, deep SSI, wound complications, sepsis, aseptic revision reported for those with cutaneous psoriasis

Mean Total Improvement Score significantly improved at week 52; brepocitinib was superior for all nine secondary outcomes

Topical timolol maleate 0.5 percent gel applied three times daily for 24 weeks is effective and safe

Patients with CLL have increased risk for most skin cancer subtypes and higher risk for skin cancer-specific metastasis and death

Experts warn tanning beds raise skin cancer risk